The April 2026 list price As of April 2026, semaglutide carries a U.S
Since chronic inflammation can deplete glutathione, it makes sense that anti-inflammatory substances can have the opposite effect
Like blockage of the small intestine, bowel obstructions could lead to tissue death, peritonitis, or sepsis without proper treatment
If orforglipron receives approval for obesity in April 2026, it will enter a market that Morgan Stanley estimates could reach $100 billion annually by the early 2030s, potentially transforming Eli Lilly's already dominant position in the metabolic disease space
Jody Dushay, an endocrinologist at Beth Israel Deaconess Medical Center and assistant professor of medicine at Harvard Medical School, said she doesnt support the use of compounded GLP-1 drugs but also worries that restrictions could add new strain to the overall supply